获得性BRAF重排介导EGFR突变肺癌对EGFR治疗的继发性耐药
研究对374例转移性EGFR突变肺癌患者样本行靶向大panel测序,发现4例(2.3%)在EGFR-TKI耐药后出现BRAF融合(3例AGK/BRAF,1例PJA2/BRAF)。细胞实验表明AGK/BRAF融合可激活BRAF/MEK/ERK通路并导致奥希替尼耐药,曲美替尼与奥希替尼协同抑制生长,pan-RAF抑制剂单药亦可阻断生长。作者认为BRAF融合是约2%患者EGFR-TKI获得性耐药机制,联合抑制EGFR和MEK或BRAF是值得探索的治疗策略。
要点
- EGFR-TKI耐药后2.3%(4/374)患者检出BRAF融合,其中3例AGK/BRAF、1例PJA2/BRAF。
- AGK/BRAF融合在细胞中激活BRAF/MEK/ERK/STAT3并导致奥希替尼耐药。
- 曲美替尼与奥希替尼协同,pan-RAF抑制剂单药亦可阻断BRAF融合细胞生长。
核心结论
- BRAF融合是约2%EGFR突变肺癌患者对EGFR-TKI获得性耐药的机制。
- 联合抑制EGFR和MEK(奥希替尼联合曲美替尼)或抑制BRAF(pan-RAF抑制剂)是值得探索的潜在治疗策略。
研究设计与样本
- 对374例连续转移性EGFR突变肺癌患者样本行靶向大panel测序,其中174例为TKI后样本,38例有配对TKI前样本。
- 通过CRISPR/Cas9基因组编辑将推测导致获得性耐药的变异引入药物敏感EGFR突变肺癌细胞系(H1975、HCC827、PC9)。
- 从一例EGFR-TKI耐药患者样本建立携带EGFR外显子19缺失和PJA2/BRAF融合的细胞系MSK-LX138cl。
主要发现
- 在EGFR-TKI获得性耐药样本中鉴定出4例(2.3%)BRAF融合:3例AGK/BRAF和1例PJA2/BRAF。
- 4例中2例为奥希替尼后样本,2例为奥希替尼和奥希替尼后样本;2例有TKI前样本且均为BRAF融合阴性。
- 在H1975(L858R+T790M)、PC9(ex19del)和HCC827(ex19del)细胞中诱导AGK/BRAF融合可增加BRAF、MEK1/2、ERK1/2和STAT3磷酸化,并赋予对奥希替尼生长抑制的耐药。
- 曲美替尼抑制MEK与奥希替尼协同阻断生长;pan-RAF抑制剂单药可阻断所有携带EGFR突变和BRAF融合的细胞系生长。
临床怎么用
- 作者认为联合抑制EGFR和MEK(奥希替尼联合曲美替尼)或抑制BRAF(pan-RAF抑制剂)是值得探索的潜在治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Multiple genetic mechanisms have been identified in EGFR-mutant lung cancers as mediators of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs), but many cases still lack a known mechanism. METHODS: To identify novel mechanisms of AR, we performed targeted large panel sequencing of samples from 374 consecutive patients with metastatic EGFR-mutant lung cancer, including 174 post-TKI samples, of which 38 also had a matched pre-TKI sample. Alterations hypothesized to confer AR were introduced into drug-sensitive EGFR-mutant lung cancer cell lines (H1975, HCC827, and PC9) by using clustered regularly interspaced short palindromic repeats/Cas9 genome editing. MSK-LX138cl, a cell line with EGFR exon 19 deletion (ex19del) and praja ring finger ubiquitin ligase 2 gene (PJA2)/BRAF fusion, was generated from an EGFR TKI-resistant patient sample. RESULTS: We identified four patients (2.3%) with a BRAF fusion (three with acylglycerol kinase gene (AGK)/BRAF and one with PJA2/BRAF) in samples obtained at AR to EGFR TKI therapy (two posterlotinib samples and two posterlotinib and postosimertinib samples). Pre-TKI samples were available for two of four patients and both were negative for BRAF fusion. Induction of AGK/BRAF fusion in H1975 (L858R + T790M), PC9 (ex19del) and HCC827 (ex19del) cells increased phosphorylation of BRAF, MEK1/2, ERK1/2, and signal transducer and activator of transcription 3 and conferred resistance to growth inhibition by osimertinib. MEK inhibition with trametinib synergized with osimertinib to block growth. Alternately, a pan-RAF inhibitor as a single agent blocked growth of all cell lines with mutant EGFR and BRAF fusion. CONCLUSION: BRAF fusion is a mechanism of AR to EGFR TKI therapy in approximately 2% of patients. Combined inhibition of EGFR and MEK (with osimertinib and trametinib) or BRAF (with a pan-RAF inhibitor) are potential therapeutic strategies that should be explored.
引用
- Vojnic M, Kubota D, Kurzatkowski C, et al. Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. J Thorac Oncol. 2019. PMID: 30831205. doi:10.1016/j.jtho.2018.12.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。